Mereo Biopharma Group PLC
NASDAQ:MREO

Watchlist Manager
Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC
NASDAQ:MREO
Watchlist
Price: 3.72 USD 1.09% Market Closed
Market Cap: 572.3m USD
Have any thoughts about
Mereo Biopharma Group PLC?
Write Note

Relative Value

MREO latest financial reports are more than 2 years old.

The Relative Value of one MREO stock under the Base Case scenario is 2.28 USD. Compared to the current market price of 3.72 USD, Mereo Biopharma Group PLC is Overvalued by 39%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MREO Relative Value
Base Case
2.28 USD
Overvaluation 39%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
3
vs Industry
20
Median 3Y
4.4
Median 5Y
0
Industry
7.7
Forward
39.3
vs History
vs Industry
Median 3Y
-6.5
Median 5Y
-6.4
Industry
22.7
Forward
-27.1
vs History
vs Industry
Median 3Y
-9.5
Median 5Y
-15.5
Industry
21.6
vs History
vs Industry
Median 3Y
-11.7
Median 5Y
-22.5
Industry
25.2
vs History
23
vs Industry
8
Median 3Y
2.4
Median 5Y
2.8
Industry
2.5
vs History
6
vs Industry
18
Median 3Y
2.3
Median 5Y
0
Industry
7.7
Forward
31.8
vs History
20
vs Industry
11
Median 3Y
41.8
Median 5Y
4.4
Industry
9
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-7.3
Industry
4.2
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-7.2
Industry
4.1
Forward
-16.5
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-13.5
Industry
5.7
vs History
vs Industry
Median 3Y
-6.2
Median 5Y
-13.5
Industry
3.6
vs History
7
vs Industry
10
Median 3Y
3.5
Median 5Y
5.3
Industry
4.6

Multiples Across Competitors

MREO Competitors Multiples
Mereo Biopharma Group PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Mereo Biopharma Group PLC
NASDAQ:MREO
573.9m USD 45.7 -9 -7.4 -7.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
UK
Mereo Biopharma Group PLC
NASDAQ:MREO
Average P/E: 208.3
Negative Multiple: -9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
UK
Mereo Biopharma Group PLC
NASDAQ:MREO
Average EV/EBITDA: 17.2
Negative Multiple: -7.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
UK
Mereo Biopharma Group PLC
NASDAQ:MREO
Average EV/EBIT: 22.5
Negative Multiple: -7.2
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top